CYTK Reports $4.8M Net Product Revenue, $1.1B Cash, Launches MYQORZO in U.S., EC Approval, ACACIA-HCM Meets Dual Endpoints, FDA NDA Accepted with Nov 14 PDUFA, ~275 HCPs Prescribe to 680 Patients, Germany Launch Q2 2026
Cytokinetics Inc. · PHARMACEUTICAL PREPARATIONS · Now $76.76
-2.9% in 1d after detection
Post-detection moves
1h
—
1d
-2.9%
3d
-0.2%
7d
+2.0%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS